In cabg case cam we give labetalol in high bp
Reading File
Searching the Web
labetalol post-CABG hypertension management
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Here is a detailed, evidence-based answer:
Labetalol in Post-CABG Hypertension
Yes, IV labetalol can be used for hypertension after CABG, but with important nuances depending on the patient's hemodynamic status.
Why Labetalol Works Well Post-CABG
Labetalol is a combined alpha-1 and non-selective beta blocker (alpha:beta ratio ~1:7 IV). In the post-CABG setting:
- It lowers BP without causing reflex tachycardia (beta blockade prevents this)
- Reduces myocardial oxygen demand (heart rate + afterload both fall)
- A classic study by Sladen et al. (1990) showed IV labetalol successfully controlled post-CABG hypertension in 85% of patients (55/65), with 46 responding to 35 mg or less
According to Textbook Guidelines
From Comprehensive Clinical Nephrology (7th Ed.) - Table 36.2 on perioperative/postoperative hypertension:
| Surgery Type | First-Choice Drugs | Second-Choice / Additional |
|---|---|---|
| Coronary artery surgery | Nitroglycerin, nicardipine, clevidipine | Esmolol, labetalol, fenoldopam, isradipine |
So for coronary artery surgery specifically, labetalol is listed as a second-choice / additional agent (with nitroglycerin and nicardipine preferred first).
From Morgan & Mikhail's Clinical Anesthesiology (7th Ed.):
"Mild to moderate elevations can be treated with intravenous labetalol, an ACE inhibitor such as enalapril, or a calcium channel blocker such as nicardipine." "Marked hypertension in patients with limited cardiac reserve requires direct intraarterial pressure monitoring and should be treated with an IV infusion of nitroprusside, nitroglycerin, nicardipine, clevidipine, or fenoldopam."
When to Be Cautious / Avoid Labetalol Post-CABG
| Situation | Concern |
|---|---|
| Low cardiac output / cardiogenic shock | Beta-blockade worsens myocardial depression |
| Acute heart failure / pulmonary edema | Beta-blockers are listed as drugs to avoid in this setting |
| Bradycardia or high-degree AV block | Further slows heart rate |
| Severe bronchospasm / reactive airway disease | Non-selective beta blockade |
| Marked hypertension with poor cardiac reserve | Prefer nitroprusside, nitroglycerin, nicardipine, or clevidipine infusions instead |
Practical Summary
- Mild-to-moderate post-CABG hypertension with preserved cardiac function: Labetalol is appropriate and effective - give as IV boluses (5-20 mg, repeat every 10 min as needed, max ~300 mg cumulative)
- Post-CABG hypertension with good cardiac output, tachycardia, or anxiety component: Labetalol is a good choice (controls both BP and heart rate)
- If cardiac output is low or heart failure is present: Avoid labetalol - use nitroglycerin or nicardipine/clevidipine infusions instead
- First-line agents for coronary surgery specifically: Nitroglycerin, nicardipine, and clevidipine are preferred by most guidelines; labetalol is a valid second-line or adjunct
The key is patient selection - labetalol is safe and effective post-CABG when LV function is adequately preserved.
Can we give trenexamic acid if nasal bleeding present in them
Finding Sources
Searching the Web
tranexamic acid epistaxis nasal bleeding post-CABG safety
Reading File
Reading File
Here is a complete, textbook-backed answer:
Tranexamic Acid (TXA) for Epistaxis in a Post-CABG Patient
Short Answer
Yes - topical TXA is preferred and is relatively safe. Systemic TXA requires more caution in post-CABG patients due to thrombotic risk, but topical application has minimal systemic absorption and is well-supported by evidence.
How TXA Works for Epistaxis
TXA is an antifibrinolytic - it blocks plasminogen binding to fibrin, preventing clot breakdown. This stabilizes the forming clot at the bleeding site without actively promoting new clot formation.
"Tranexamic acid does not increase fibrin deposition and so does not increase the risk of thrombosis."
- Scott-Brown's Otorhinolaryngology Head & Neck Surgery
Evidence for TXA in Epistaxis
From Rosen's Emergency Medicine (textbook evidence):
- A systematic review and meta-analysis found moderate quality evidence supporting topical TXA in reducing bleeding at 10 minutes and re-bleeding at 7-10 days
- No significant increase in adverse events among TXA-treated patients
- One landmark trial (Zahed et al.) showed topical TXA was superior to anterior nasal packing specifically in patients taking antiplatelet drugs (very relevant post-CABG, since these patients are almost always on aspirin ± clopidogrel)
Route of Administration - Critical Distinction in Post-CABG
| Route | Post-CABG Consideration |
|---|---|
| Topical TXA (500 mg IV solution soaked on nasal pledget, or atomized) | Preferred - minimal systemic absorption, negligible thrombotic risk, effective |
| Oral TXA (1.5 g three times a day) | Use with caution - systemic antifibrinolytic effect; assess thrombotic risk individually |
| IV TXA | Generally avoid unless life-threatening hemorrhage - highest systemic thrombotic risk post-CABG |
The Key Concern in Post-CABG Patients
Post-CABG patients are at elevated risk for:
- Graft thrombosis (especially in the first weeks)
- They are on dual antiplatelet therapy (aspirin + clopidogrel/ticagrelor)
The paradox here is that antiplatelet therapy makes them bleed more (hence the epistaxis), but systemic antifibrinolytics could increase graft thrombosis risk.
Topical TXA elegantly solves this dilemma - it controls local nasal bleeding without meaningfully raising systemic clotting activity.
From the NZ data sheet (official prescribing information): "Tranexamic acid solution for injection may be applied topically to the nasal mucosa of patients suffering from epistaxis. This can be done by soaking a gauze strip in the solution and then packing the nasal cavity."
Contraindications to Note
Per Scott-Brown's Otorhinolaryngology:
- Pre-existing thromboembolic disease is a contraindication to systemic TXA
- Recent CABG/stenting with fresh grafts falls into this high-risk thrombotic category - so avoid systemic routes; topical is acceptable
Practical Approach for Post-CABG Epistaxis
- First-line: Direct pressure (10-15 min), topical vasoconstrictors (oxymetazoline)
- Add topical TXA: 500 mg of IV solution soaked onto a nasal pledget - effective and safe even in antiplatelet patients
- Avoid stopping antiplatelet therapy for epistaxis (graft thrombosis risk outweighs nasal bleed risk)
- Do NOT give systemic/IV TXA for routine epistaxis post-CABG - the thrombotic risk to the bypass grafts is not justified for a nasal bleed
- If refractory - ENT referral for cautery or packing
This is a shared conversation. Sign in to Orris to start your own chat.